• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
  • MANUFACTURERS
  • HEADHUNTERS
  • PRODUCT SECTIONS
  • COMPANIES

SPINEMarketGroup

Spine Industry News

  • HOME
  • 2025
  • 2024
  • BROCHURES
  • ARTICLES
  • VIDEOS

SpineGuard Reports Six-Month 2022 Financial Results

September 16, 2022 By SPINEMarketGroup

SpineGuard (FR0011464452 – ALSGD) (Paris:ALSGD), an innovative company that deploys its DSG® (Dynamic Surgical Guidance) sensing technology to secure and streamline the placement of bone implants, announced today financial results for the half year ending June 30, 2022, as approved by the Board of Directors on September 15, 2022.

Pierre JEROME, cofounder, Chairman & CEO of SpineGuard, said: “These half year results are in line with our financial objectives. They reflect our strategy to invest selectively in both the strengthening of our US commercial structure and the further deployment of our DSG technology while remaining close to break-even and minimizing dilution for our shareholders. Our cash runway and growth prospects, in particular those related to the two new strategic partnerships initiated this year, enable us to be confident and enthusiastic about SpineGuard’s future.”

EBITDA improves by 15%

2,848 DSG units were sold in the first half of 2021 compared with 2,731 in the first half of 2021, including 1,340 in the United States, representing 47% of total units sold.

Revenue was still impacted by the COVID-19 pandemic early 2022. For H1 2022, the Company reported revenues of € 2,546 K, up 14% as reported in H1 2021 and +6.5% in constant currency compared with H1 2021.

Gross margin of 84.9% at June 30, 2022 improved by 3.9%. ASP’s remained globally stable and while the company faced some higher costs of manufacturing, they remained limited overall. The return to growth also reduced the impact of the scraps of obsolete inventory in the USA incurred in 2021.

Operating expenses were € 3,131 K for H1 2022, compared with € 2,506 K, an increase of € 625 K compared with June 30, 2021 driven by the momentum of sales & marketing initiatives in the US.

The net operating loss stands at € -964 K vs. € -692 K at June 30, 2021.

EBITDA improved 15% at € -561 K compared to € -661 K at June 30, 2021.

Working capital requirements were € 247 K compared with € -133 K at December 31, 2021 mainly due to the increase of account receivables (+€ 271 K) and inventory (+€ 141 K).

At June 30, 2022, cash and cash equivalents were € 4,450 K compared with € 5,207 K at December 31, 2021, and is explained as follows:

  • Operating cash flow of € -921 K compared with the same period last year of € -620 K.
  • Equity funding using the equity lines for a gross amount of € 1,006 K throughout the period.
  • The payment of interests to Norgine Ventures and Harbert European Growth of € 157 K.
  • Reimbursement of the principal of the venture loans for € 336 K over the half-year.

The cash position as of August 31, 2022 of € 3.7 M plus the secured equity line facility for € 4.0 M means that the total cash available to the Company is € 7.7 M. Considering the current cash position, the secured convertible bond facility and the recurring expected business, the Company estimates that it can fund its needs through mid-2024.

Post-closing events

SpineGuard and Omnia Medical, a medical device company focused on innovative solutions utilizing proven techniques, announced the signature of a co-development and exclusive distribution agreement for adult spine surgery in the United States. This partnership spans two novel devices: a smart single-step pedicle screw system and a smart drilling tool for sacroiliac joint fusion both embedding the DSG (Dynamic Surgical Guidance) technology.

SpineGuard’s Priorities

SpineGuard is focusing on the following priorities while investing selectively to remain close to breakeven:

  1. Boost commercial activities with the launch of the DSG-Connect visual interface and the partnership with WishBone Medical
  2. Deploy the DSG digital technology in the surgical robotic field
  3. Develop a Smart Universal Drill (SUD) embedding the DSG artificial intelligence
  4. Support ConfiDent with the design and scale-up of the DSG dental applications
  5. Implement the agreement recently signed with Omnia Medical
  6. Sign other strategic partnerships

The company’s half-year financial report is available in the Investors > Exchange filings section of the www.spineguard.com website in French only.

Next financial press release: Third quarter 2022 revenue on October 12, 2022, after market closing.

About SpineGuard®

Founded in 2009 in France and the USA by Pierre Jérôme and Stéphane Bette, SpineGuard is an innovative company deploying its proprietary radiation-free real time sensing technology DSG® (Dynamic Surgical Guidance) to secure and streamline the placement of implants in the skeleton. SpineGuard designs, develops and markets medical devices that have been used in over 90,000 surgical procedures worldwide. Nineteen studies published in peer-reviewed scientific journals have demonstrated the multiple benefits DSG® offers to patients, surgeons, surgical staff and hospitals. Building on these strong fundamentals and several strategic partnerships, SpineGuard has expanded the scope of its DSG® technology in innovative applications such as the « smart » pedicle screw, the DSG Connect visualization and registration interface, dental implantology and surgical robotics. DSG® was co-invented by Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer. SpineGuard has engaged in multiple ESG initiatives.

For further information, visit www.spineguard.com

Disclaimer

The SpineGuard securities may not be offered or sold in the United States as they have not been and will not be registered under the Securities Act or any United States state securities laws, and SpineGuard does not intend to make a public offer of its securities in the United States. This is an announcement and not a prospectus, and the information contained herein does and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in the United States in which such offer, solicitation or sale would be unlawful prior to registration or exemption from registration.

Contacts

NewCap
Mathilde Bohin / Aurélie Manavarere
Investor Relations & Strategic Communication
Phone nb.: 01 44 71 94 94
Email: [email protected]

SpineGuard
Pierre Jérôme
Chairman and CEO
Phone nb.: 01 45 18 45 19
Email: [email protected]

(Visited 98 times, 9 visits today)

Filed Under: NEWS, RESULTS Tagged With: 2022, NEWS

Primary Sidebar

PLATINUM SPONSORS

GOLD SPONSORS

MOST POPULAR POSTS

  • BROCHURES
  • Just Reflective, Not Disappointed: Globus Medical’s…
  • What’s Happening with Globus Medical? Why Has the…
  • (UPDATED 2025): 6 Artificial Cervical Discs You’ll…
  • The Crown Is Still Medtronic’s… For Now!
  • (UPDATED 2024): +8 Lumbar Artificial Discs to Know…
  • After Diabetes, Could Medtronic’s Spine…
  • Globus Medical to Execute $500 Million Share Buyback…
  • Globus Medical extends versatility of Advanced…
  • Stryker’s Spine Business Sale: A Smart Move or a…
  • Eminent Spine’s 3D Printed Titanium Pedicle Screw…
  • M6 Discontinued: What Are the Alternatives for a…
  • Dispute Over Spinal Implant Royalties Between…
  • Orthofix Discontinues M6-C™ and M6-L™ Artificial…
  • Top Expandable Cages of 2025: Which Lumbar Implants…
  • (UPDATED 2024): +108 Stand-Alone Cervical Cages to Know..!
  • (Updated!) 15 Expandable PLIF Cages to Know…!
  • Globus Medical Reports First Quarter 2025 Results
  • Stryker’s Spine Exit: What It Means for…
  • Viscogliosi Brothers Completes Acquisition of U.S.…
  • LAST 10 VIDEOS PUBLISHED

    1. Biedermann Motech: MOSS 100 (Short)
    2. POWEHI MEDICAL AG: KUDOS™ Modular
    3. POWEHI MEDICAL AG: TANTO® Screw
    4. Syntropiq: Taurus TLIF (Short)
    5. LEM Surgical: Dynamis Surgical Robot
    6. Aegis Spine:PathLoc-TA
    7. NGMedical: MOVE®-C Artificial Disc
    8. B.Braun Aesculap: Ennovate® Cervical MIS
    9. Spineart: PERLA® TL Deformity Solutions
    10. NGMedical: MOVE®-C

    Recent Comments

    • Peter on A New Player in Spinal Care, POWEHI Medical!
    • Sandy on Just Reflective, Not Disappointed: Globus Medical’s Bittersweet Q1 2025
    • SPINEMarketGroup on M6 Discontinued: What Are the Alternatives for a Cervical Artificial Disc?
    • Sergio López-Fombona on M6 Discontinued: What Are the Alternatives for a Cervical Artificial Disc?
    • Drew on Has Globus Already Surpassed Medtronic in the Spine Market? Can J&J Find Its Way Back to the Top?
    • Ahmed Hassan El-Naggary on Has Globus Already Surpassed Medtronic in the Spine Market? Can J&J Find Its Way Back to the Top?
    • Email
    • Twitter
    • YouTube

    Subscribe to Our Newsletter!

    Check your inbox or spam folder to confirm your subscription.

    Footer

    • Email
    • Twitter
    • YouTube

    Contact us:

    [email protected] [email protected]

    PRIVATE POLICY

    • Legal Advice
    • Embed Link
    • VIDEOS

    Copyright © 2025 · SPINEMarketGroup

    Manage Cookie Consent
    To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
    Functional Always active
    The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
    Preferences
    The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
    Statistics
    The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
    Marketing
    The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
    Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
    View preferences
    {title} {title} {title}